Results 151 to 160 of about 52,744 (222)

Literature review of myasthenia gravis complicated by myocardial damage. [PDF]

Medicine (Baltimore)
Lei C, Chen J, Chen Z, Xie L, Wu D, Jiang J.   +5 more
europepmc   +1 more source

Role of Extracellular Vesicles in Shaping Immune Responses in the Lymph Node Microenvironment

Biology of the Cell, Volume 118, Issue 10, October 2026.
Functional alliances of stromal, innate and adaptive immune cells in EV immunity in the lymph node. EV reflect the phenotype of their mother cell and cluster material from their surroundings. In the lymph node, EV preserve valuable context information between multiple cellular effectors to coordinate immunity in adaption to change.
Alicia Charrier, Apolline Salama, Laurence Dubreil, Grégoire Mignot, Steffi Bosch   +4 more
wiley   +1 more source

Exosomes in Myasthenia Gravis-Review. [PDF]

Cells
Ejdys K, Mycko MP.
europepmc   +1 more source

Co‐Occurrence of Facioscapulohumeral Muscular Dystrophy and Myasthenia Gravis: A Systematic Review and Meta‐Analysis of Individual Patient Data

European Journal of Neurology, Volume 33, Issue 10, October 2026.
ABSTRACT Background Co‐occurrence of facioscapulohumeral muscular dystrophy (FSHD) and myasthenia gravis (MG) is rare but clinically critical, as treatable MG symptoms may be misattributed to FSHD progression. This systematic review and meta‐analysis aimed to comprehensively characterize patients with both conditions and to quantitatively synthesize ...
Pricilla Yani Gunawan, Jeremiah Hilkiah Wijaya   +1 more
wiley   +1 more source

Clinical study of eculizumab with or with not tacrolimus in the treatment of generalized myasthenia gravis. [PDF]

Front Immunol
Yang B, Wang J, Zhao X, Jing C, Yin J, Qiao L.   +5 more
europepmc   +1 more source

Journal Club Update: Myasthenia Gravis

, 2014
Brief overview of major or interesting papers on the topic of Myasthenia Gravis in the last 2 years Review of the conclusion of the two major studies of the use of mycophenolate mofetil in ...
Judith E. A. Warner, MD
core  

Advances in the treatment of systemic lupus erythematosus: Biologicals, small‐molecular agents, and cell‐depleting therapies coming to the clinic

Journal of Internal Medicine, Volume 300, Issue 4, Page 461-479, October 2026.
Abstract Systemic lupus erythematosus (SLE; lupus) remains a particular challenge for the practicing clinician on account of its chronic undulating and unpredictable course, its diverse manifestations, and—until recently—limited treatment options all associated with considerable downsides.
Ronald van Vollenhoven
wiley   +1 more source

Treatment of Ocular Myasthenia Gravis

, 2019
Myasthenia gravis is caused by pathogenic autoantibodies to the postsynaptic neuromuscular junction. Clinically, this may affect any of the skeletal muscles causing variable weakness, which worsens with continued muscle activity. Ocular myasthenia gravis
Michael Lee
core  

Women and Myasthenia Gravis. [PDF]

Ann Indian Acad Neurol
Menon D, Vengalil S, Nashi S, Nalini A.
europepmc   +1 more source

Possible involvement of viral infection in the pathogenesis of myasthenia gravis. [PDF]

J Neurovirol
Dolci M, Signorini L, Perego F, Passerini S, Giannasi C, Camurri F, Berni A, Messina S, Pietropaolo V, Baj A, Cavalcante P, Delbue S.   +11 more
europepmc   +1 more source